Testing immune cells from specific AMD eye types
Treatments studied
Part of Eyes & vision clinical trials.
This study collects immune cells (from a blood sample) from people with certain types of age-related macular degeneration (AMD) and compares how long they live. It may help researchers understand how immune-related changes relate to AMD outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 50 or older
- You can give written consent (and you’re not under guardianship/curatorship)
- You’re connected to French social security
- You weigh at least 50 kg
- You have the right eye situation: atrophic AMD in both eyes, early+atrophic, early+exudative, or no retinal problem (control)
- You’re not taking immune-changing medicines like immunosuppressants, immunomodulators, chemotherapy, or corticosteroids
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a library of eye images to help doctors better diagnose age-related macular degeneration (AMD). You can join if you have healthy eyes or any stage of AMD that has never been treated.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This study uses eye imaging and other tests to predict if early age-related macular degeneration (AMD) will progress to a more advanced stage. It aims to help doctors identify who might need closer monitoring in the future.
This study looks closely at how age-related macular degeneration (AMD) develops and changes over time by taking detailed eye measurements. It may help researchers better understand disease progression, especially for people who already have AMD.
This study tracks how age-related macular degeneration (AMD) progresses over time and looks at factors that might affect your vision and quality of life. By participating, you'll help researchers understand more about AMD and what might predict better or worse outcomes.
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.